References
FIGURE LEGENDS
FIGURE 1: MTHFR genotype effect on maximum tolerated C-MTX and HDMTX clearance times. Maximum tolerated C-MTX (A) and HDMTX clearance times for each patient were plotted according to specific MTHFR genotype. *, p < 0.05; n.s., not significant. MTX, methotrexate.
FIGURE 2: Oral MTX and 6-MP during maintenance therapy. Maximum tolerated doses of oral MTX (A) and oral 6-MP (B) were obtained for each patient and plotted according to specific MTHFR genotype. (C & D) 6-MP metabolite data for 6-TG and 6-MMP were obtained from patient records while they were on 100% recommended protocol dosing and compare to maximum tolerated oral 6-MP dose (C) or maximum tolerated oral dose (D). *, p < 0.05; **, p < 0.01; n.s., not significant: MTX, methotrexate; 6-MP, 6-mercaptopurine; 6-TG, 6-thioguanine; 6-MMP, 6-methylmercaptopurine; RBC, red blood cell.
FIGURE 3: Toxicities triggering the assessment of MTHFR genotype status. The causal reason for sending MTHFR genetic testing for each patient was obtained from the medical record and broadly categorized into groups listed in figure. Note: for patients who had no documentation for sending of MTHFR genetic testing, classification group unknown was used.